Acute Coronary Syndrome Clinical Trial
Official title:
European Registry on Patients With ST-Elevation MI Transferred for Mechanical Reperfusion (PCI)With a Special Focus on Upstream Use of Abciximab
Verified date | June 2007 |
Source | Jagiellonian University |
Contact | n/a |
Is FDA regulated | No |
Health authority | Poland: Ministry of Health |
Study type | Observational |
EUROTRANSFER Registry is a prospective, international, web-based European Registry on
Patients with ST-Elevation MI Transferred for Mechanical Reperfusion (PCI) with a Special
Focus on Upstream Use of Abciximab.
This registry is designed to collect data on approximately 1800 patients during a 12 month
enrollment period in up to 20 interventional cardiology centres with hospital transfer
networks from all over Europe.
Analysis of this registry should allow to monitor transfer timelines of patients arriving to
the cath-lab from the regional hospital with or without upstream start of abciximab and
scheduled for mechanical reperfusion (PCI) as well as to monitor regional differences across
Europe in regard to the impact that time of various stages of the treatment chain may have
on clinical outcomes.
Status | Completed |
Enrollment | 1800 |
Est. completion date | February 2007 |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: PATIENTS: - All consecutive STEMI patients >=18years arriving to the Cath Lab hospital (invasive facility center) from transfer. - Transfer with respect to this registry is defined as patients that reach the Cath Lab hospital: 1. transferred from a surrounding regional community hospitals that the Cath Lab hospital has an established referral pattern with or 2. after being picked–up by an ambulance which is equipped/staffed to provide specific medical therapy (like prehospital thrombolysis or upstream abciximab). Usually these have a physician or specifically trained nurse on board. CENTRES: - Provide 24 hour/7 days on duty PCI service. - Has an established regional hospital referral network with >=8 patients/month arriving from transfer (as defined above). - A rate of >=10% of these transfer patients who receive upstream abciximab before or during transfer to the Cath Lab hospital. Start of abciximab in the ER or CCU of the Cath Lab hospital will not be considered as upstream start of abciximab. Exclusion Criteria: - Patients who arrive to the Cath Lab from other pathways than those specified above (a. and b.), e.g. those who come by ambulances that do not provide specific medical therapy or arrive directly to the ER of the Cath Lab hospital by own feet/car will not be included in this registry. - Patients from controlled clinical trials shall be included as long as their actual treatment is fully known. Thus, participants from randomized trials with blinded treatment cannot be included in this registry. |
Observational Model: Defined Population, Time Perspective: Cross-Sectional
Country | Name | City | State |
---|---|---|---|
Finland | Helsinki University Central Hospital | Helsinki | |
Germany | Schwarzwald-Baar Klinikum Villingen-Schwenningen GmbH | Villingen | |
Italy | San Donato Hospital | Arezzo | |
Italy | Ospedale Carlo Poma | Mantova | |
Italy | Ospedale G.Pasquinucci | Massa | |
Italy | Santa Maria Nuova Hospital Reggio Emilia | Reggio Emilia | |
Italy | Ospedale S.Maria di Ca Foncello | Treviso | |
Poland | Cardiac Catheterization Laboratories Jagiellonian University Medical College, University Hospital | Krakow | |
Poland | Department of Interventional Cardiology, John Paul II Hospital | Krakow | |
Poland | Szpital Wojewodzki w Przemyslu | Przemysl | |
Poland | Szpital im. Szczeklika Tarnow | Tarnow | |
Slovenia | University Medical Center Ljubljana | Ljubljana | |
Spain | Hospital Juan Canalejo | Coruna | |
Spain | Hospital Clinico Universitario | Santiago de Compostela | |
Sweden | Linköping University Hospital | Linköping |
Lead Sponsor | Collaborator |
---|---|
Jagiellonian University | Foundation for Medical Research in Krakow, Poland |
Finland, Germany, Italy, Poland, Slovenia, Spain, Sweden,
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05846893 -
Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease
|
N/A | |
Recruiting |
NCT06013813 -
Conventional vs. Distal Radial Access Outcomes in STEMI Patients Treated by PCI
|
N/A | |
Recruiting |
NCT05412927 -
AngelMed Guardian® System PMA Post Approval Study
|
||
Completed |
NCT02750579 -
Early or Delayed Revascularization for Intermediate and High-risk Non ST-elevation Acute Coronary Syndromes?
|
N/A | |
Completed |
NCT04102410 -
Assessing Force-velocity Profile: an Innovative Approach to Optimize Cardiac Rehabilitation in Coronary Patients
|
N/A | |
Enrolling by invitation |
NCT03342131 -
Serum Concentration of Wnt2 and Wnt4 in Patients With Acute Coronary Syndrome
|
N/A | |
Recruiting |
NCT01218776 -
International Survey of Acute Coronary Syndromes in Transitional Countries
|
||
Enrolling by invitation |
NCT04676100 -
International CR Registry
|
||
Completed |
NCT03590535 -
5th Generation cTnT in ED ACS
|
||
Recruiting |
NCT05437900 -
INSIGHTFUL-FFR Clinical Trial
|
Phase 4 | |
Completed |
NCT05551429 -
Factors Related to Participation in Cardiac Rehabilitation in Patients With Acute Coronary Syndrome
|
||
Terminated |
NCT04316481 -
IDE-ALERTS Continued Access Study
|
N/A | |
Active, not recruiting |
NCT04475380 -
Complex All-comers and Patients With Diabetes or Prediabetes, Treated With Xience Sierra Everolimus-eluting Stents
|
||
Not yet recruiting |
NCT04852146 -
Electronic Feedback for Data Restitution and Valorization to the Emergency Teams in Aquitaine.
|
||
Active, not recruiting |
NCT02892903 -
In the Management of Coronary Artery Disease, Does Routine Pressure Wire Assessment at the Time of Coronary Angiography Affect Management Strategy, Hospital Costs and Outcomes?
|
N/A | |
Completed |
NCT04077229 -
Piloting Text Messages to Promote Positive Affect and Physical Activity
|
N/A | |
Completed |
NCT02944123 -
Half Dose of Prasugrel and Ticagrelor in Acute Coronary Syndrome (HOPE-TAILOR)
|
Phase 3 | |
Not yet recruiting |
NCT02871622 -
BMX Alpha Registry: a Post-market Registry of the BioMatrix Alpha TM
|
N/A | |
Active, not recruiting |
NCT02922140 -
The Impact of Pharmaceutical Care Practice on Patients in Cardiac Rehabilitation Unit
|
N/A | |
Terminated |
NCT02620202 -
Aiming Towards Evidence Based Interpretation of Cardiac Biomarkers in Patients Presenting With Chest Pain
|